Moreover, work by Mittendorf et al. [305] indicated that treatments with rapamycin, an mTOR inhibitor, dramatically reduce PD-L1 mRNA transcripts in PTEN-mutant triple-negative breast cancer cell lines. Here, MTOR is linked to triple-negative breast carcinoma.